Author: Relay Therapeutics, Inc.

Posted Date:

May 5, 2026

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

Relay Therapeutics, Inc.

May 5, 2026
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

Relay Therapeutics, Inc.

April 29, 2026
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

Relay Therapeutics, Inc.

April 27, 2026
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

Relay Therapeutics, Inc.

April 2, 2026
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

Relay Therapeutics, Inc.

March 16, 2026
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

Relay Therapeutics, Inc.

February 26, 2026
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March

Relay Therapeutics, Inc.

February 23, 2026
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

Relay Therapeutics, Inc.

February 19, 2026
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Relay Therapeutics, Inc.

February 7, 2026
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

Relay Therapeutics, Inc.

February 3, 2026